The mechanisms governing vascular smooth muscle tone are incompletely understood. In particular, the role of the sarcolemmal calcium pump PMCA (plasma membrane calmodulin-dependent calcium ATPase), which extrudes Ca 2؉ from the cytosol, and its importance compared with the sodium/calcium exchanger remain speculative. To test whether the PMCA is a regulator of vascular tone, we generated transgenic mice overexpressing the human PMCA4b under control of the arterial smooth muscle-specific SM22␣ promoter. This resulted in an elevated systolic blood pressure compared with littermate controls. In PMCA-overexpressing mice, endothelium-dependent relaxation of norepinephrine-preconstricted aortic rings to acetylcholine did not differ from wild type controls (76 ؎ 8% versus 79 ؎ 8% of maximum relaxation; n ‫؍‬ 12, n.s.). De-endothelialized aortas of transgenic mice exhibited stronger maximum contraction to KCl (100 mmol/liter) compared with controls (86 ؎ 6% versus 68 ؎ 7% of reference KCl contraction at the beginning of the experiment; p <0.05).
The epidemic of cardiovascular disease has led to a particular interest in the mechanisms governing contraction of the vasculature that determine the height of blood pressure in physiological adaptation (e.g. exercise) and in pathological states such as hypertension and heart failure. The contractile state of vascular smooth muscle cells is determined by tonic and phasic contractions brought about by a complex interplay of myosin light chain phosphorylation and intracellular calcium (reviewed in Refs. 1 and 2). Outward calcium transport across the plasma membrane is maintained by two transport systems, the Na ϩ /Ca 2ϩ exchanger and the plasma membrane calmodulin-dependent calcium ATPase (PMCA). 1 The Na ϩ / Ca 2ϩ exchanger has high and the PMCA relatively low capacity for calcium transport.
Initially, it had been assumed that the exchanger has much lower Ca 2ϩ affinity than the PMCA, but this has been disputed (pump properties are summarized in Refs. [3] [4] [5] . Hence, the physiological role of the PMCA in excitable tissues that express relatively high amounts of exchanger protein has remained somewhat unclear. Four isoforms of the pump have been described, two of which (i.e. 1 and 4) are prominently expressed in peripheral extraneuronal tissues.
The PMCA itself has also been shown to be a target for post-translational modifications, e.g. phosphorylation by protein kinase A or focal adhesion kinase, influencing the activity of the pump (6 -8) . Additionally, it was suggested that the plasma membrane Ca 2ϩ pump itself may be regulated by cyclic GMP and protein kinase C in vascular smooth muscle cells (9, 10) . In an attempt to define the role of the PMCA in smooth muscle cell proliferation, Husain et al. (11) observed regulation of PMCA1 and PMCA4 mRNA transcription during cell cycle progression in vascular smooth muscle cells and showed that transient PMCA overexpression reduces the cell proliferation rate more than 2.5-fold.
In recent years, our group has developed the hypothesis that the PMCA in skeletal and heart muscle plays a more significant role in signal transduction than in regulation of calcium subserving contraction/excitation coupling (12) . Recently, a specific mechanism by which isoform 4b (also termed 4CI) of the pump exerts a regulatory role has been identified. PMCA4b has a C-terminal ligand for PDZ domains (13) (14) (15) , and we have shown that it forms a physical complex with nitric oxide synthase I (neuronal (n)NOS) and tightly regulates NO production from this (but not the endothelial) NOS isoform (16) .
In the present work, using transgenic overexpression of PMCA4b under the control of the highly vascular-specific SM22 ␣ promoter (17), we begin to define the role of the PMCA in the regulation of vascular smooth muscle cell tone. In integrated physiological systems, vascular tone translates into blood pressure, and it was therefore of particular interest to investigate whether the PMCA might be a potential candidate for blood pressure regulation.
MATERIALS AND METHODS

Generation of PMCA4b
Transgenic Mice-To generate transgenic mice, the smooth muscle-specific SM22␣ promoter (Ref. 17 ; a kind gift from M. S. Parmacek, Department of Medicine, University of Pennsylvania, Philadelphia, PA) was cloned into a vector backbone containing the human PMCA4b cDNA (accession number NM_001684) and an SV40 polyadenylation signal, as described before (12) . Six transgenic founders were obtained after standard pronucleus injection procedure; five of them gave rise to transgenic strains expressing the hPMCA4b in various artery smooth muscles of different organs. The cell line 1505.5, showing the most ubiquitous expression in smooth muscles of the vascular system, and non-transgenic littermates were used for this study.
nNOS knock-out mice B6129S-Nos1 tm1Plh and the appropriate controls B6129SF2/J ("nNOS controls") were obtained from The Jackson Laboratory, Bar Harbor, Maine. The study design and the experimental protocols were conducted according to the local institutional guidelines for the care and use of laboratory animals and are in accordance with the American Heart Association guidelines for research animal use.
Verification of Transgene Integration and Maintenance of Transgenic Lines-Integration of the used construct was verified by Southern blotting and PCR assays using tail biopsy samples. For Southern blotting assays, the human PMCA4b cDNA was used as probe. For routine use, the following human PMCA4b-specific primers were used in standard PCR assays: forward, GGCTCCCTGAGTGTACTCCC; reverse, CCTG-ATGACGGTGCTCATTG. Offspring of founders were mated to C57Bl/6 mice. Experiments were done after Ͼ4 inbred generations to C57Bl/6 background. To avoid possible insertion effects of the transgene, only transgenic mice and their littermates were used for these experiments.
Verification of Transgene Expression-Expression of transgene was tested on the mRNA level by RT-PCR and on the protein level by Western blotting and immunohistological staining. Interaction of PMCA4b with nNOS was verified by co-immunoprecipitation and subsequent Western blotting.
RT-PCR was done using 2 g of total RNA of the corresponding organ in standard reactions using the manufacturer's protocol (Qiagen onestep RT-PCR kit, Qiagen) and the hPMCA4b-specific primers (see above).
Expression of PMCA4b in aorta and interaction of nNOS with PMCA4 were detected by precipitation of PMCA4b-containing complexes and subsequent Western blotting. In brief, aortas of four transgenic and four control mice were pooled, lysed in RIPA buffer (PBS containing 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS) by Dounce homogenization. After sedimentation of cellular debris and an initial preclearing step, aorta lysates containing 300 g of protein were incubated with 5 l of anti-PMCA4 serum (SWANT) or 5 g of monoclonal mouse anti-human PMCA4b antibody (clone JA3; Neomarkers) or 5 g of irrelevant antibodies for 1 h at room temperature. PMCA4-containing complexes were precipitated with a mixture of 50 l of protein A-and G-Sepharose (Amersham Biosciences) in each sample. After incubation, the samples were washed three times with RIPA buffer, once with 50 mM Tris, pH 8.0, boiled in SDS sample buffer, separated by 8% SDS-PAGE, and blotted to a nitrocellulose membrane. Membranes were blocked with 5% nonfat milk in PBS-T (PBS with 0.05% Tween 20) and incubated for 1 h at room temperature with primary antibodies (polyclonal anti-PMCA4 serum, 1:500, SWANT; monoclonal anti-nNOS antibodies, catalogue number N41520, 1:250, Transduction Laboratories). After four washes with PBS-T, membranes were incubated with secondary horseradish peroxidase-coupled antibodies for 1 h and subsequently washed several times with PBS-T. Proteins were detected with the ECL TM detection system (Amersham Biosciences).
To show expression of transgenic human PMCA4b in smooth muscle cells of the cardiovascular system in mice, we used a polyclonal rabbit antibody, raised against a peptide consisting of the last 15 amino acid residues of human PMCA4b: LPQSDSSLQSLETSV. Endogenous PMCA4 in vascular smooth muscle cells of wild type mice was stained with a PMCA4-specific polyclonal antiserum (SWANT), cross-reactive with mouse tissue (18) . To stain for nNOS in mouse smooth muscle cells, we used the polyclonal rabbit anti-nNOS antiserum (catalogue number PA3-032A), diluted 1:500; Affinity Bioreagents.
Tissue sections were prepared according to Ref. 19 . After blocking in PBS/10% goat serum, sections were incubated overnight with primary antibodies in blocking buffer in a humid chamber at 4°C and were then washed five times in PBS. The sections were incubated with secondary antibodies (Cy3-conjugated AffiniPure goat anti-rabbit IgG, diluted 1:1000; Jackson Immunoresearch) for 1 h at room temperature in a dark chamber, followed by another five washing steps. Smooth muscle cells were counterstained with a FITC-conjugated monoclonal anti-␣-smooth muscle actin (clone 1A4, catalogue number F3777; Sigma). Stained sections were embedded in Mowiol containing 2.5% DABCO (1,4-Diazabicyclo(2.2.2)octane) and photographed after 16 h using a Zeiss Axiovert 135 microscope. An overlay of the pictures was made using Adobe Photoshop software.
Hemodynamics-Hemodynamic measurements were carried out under inhalatory isofluran anesthesia. Mice were placed on a heated board to maintain body temperature at 37°C, intubated, and connected with a rodent respirator (Harvard Apparatus). The Millar® catheter (1.4 F, model SPR671) was inserted into the right carotid artery for hemodynamic measurements. The catheter was placed into the aorta and left ventricle for respective measurements under light anesthesia.
Tissue Harvesting-Anesthetized mice (pentobarbital, 40 mg/kg body weight, intraperitoneal) were euthanized by cervical dislocation. The aorta was isolated in no-touch technique, removed, and placed immediately into cold (4°C) modified Krebs-Ringer bicarbonate solution (in Organ Chamber Experiments-Aortic rings were suspended to fine tungsten stir-ups (diameter 50 M), placed in an organ bath filled with 10 ml of Krebs solution, and connected to force transducers (Föhr Medical Instruments, Seeheim, Germany) for isometric tension recording as described before (20) . After an equilibration period of 60 min, the rings were progressively stretched to their optimal passive tension (2.0 Ϯ 0.2 g) as assessed by the response to 100 mmol/liter KCl in modified Krebs solution (21) . Rings were preconstricted with norepinephrine (10 Ϫ8 to 10 Ϫ7 mmol/liter, ϳ70% of KCl 100 mmol/liter), and relaxations to acetylcholine (10 Ϫ10 -10 Ϫ5 mol/liter) or sodium nitroprusside (10 Ϫ11 -10 Ϫ5 mol/liter) were obtained. In additional experiments, the endothelium was removed by gentle rubbing, and its absence was confirmed by the lack of relaxation to acetylcholine (3 ϫ 10 Ϫ6 mol/liter). In de-endothelialized aortic rings, cumulative concentration-response curves to KCl (1-100 mmol/liter)were obtained with and without 30 min of preincubation of the NOS inhibitor L-N(G)-nitroarginine methyl ester (L-NAME, 3 ϫ 10 Ϫ5 mol/liter), respectively. All chemical substances and drugs used in this study were purchased from Sigma.
Calculations and Statistical Analysis-Relaxations to agonists in isolated vessels are given as percentage of preconstriction in rings preconstricted with norepinephrine to about 70% of contraction induced by reference KCl (100 mmol/liter) for each vessel ring. The contractions were expressed as a percentage of 100 mmol/liter KCl-induced reference contractions, which were obtained at the beginning of every experiment for each ring. Results are presented as mean Ϯ S.E. In all experiments, n equals the number of mice per experiment. From each individual mouse three aortic rings were tested and obtained values combined. For statistical analysis, the sensitivity of the vessels to the drugs was expressed as the negative logarithm of the concentration that caused half-maximal relaxation or contraction (pD 2 ). Maximal relaxation (expressed as a percentage of preconstriction) or contraction was determined for each individual concentration-response curve by nonlinear regression analysis using MatLab software (Math Works Inc., Natick, MA). For comparison between two values, the unpaired t test or the nonparametric Mann-Whitney test was used when appropriate. For multiple comparisons, results were analyzed by analysis of variance followed by Bonferroni's correction (22) . Pearson's correlation coefficients were calculated by linear regression. A value of p Ͻ 0.05 was considered significant.
RESULTS
Expression of Transgenic hPMCA4b in Vascular Smooth
Muscle Cells-General tissue-specific transgene expression on the RNA level was determined by RT-PCR. As expected for a transgene driven by a vascular promoter, the transgenic mouse line used in this study (named 1505.5) showed ubiquitous expression in all tested organs (Fig. 1B) . Mouse lines showing expression only in a subgroup of organs were not used for further experiments (not shown). On the protein level, as determined in Western blotting experiments, the transgenic mouse line 1505.5 showed expression in liver, aorta, heart, lung, kidney, and skeletal muscle, destining this line for fur- ther studies on the role of PMCA4b in mechanisms regulating blood pressure. In some Western blots a variable migration behavior of the transgenic protein was observed, most likely because of different phosphorylation states of the protein.
To ascertain that the expression of the transgene was restricted to vascular smooth muscle cells, co-immunostaining was performed and restriction of transgene expression to vascular smooth muscles was demonstrated by staining with an antiserum generated against the C terminus of the human PMCA4b and counter-staining with directly FITC-labeled smooth muscle ␣-actin-specific antibodies (Fig. 2) . Stained sections of aorta, skeletal muscle, kidney, and liver (not shown) revealed restricted expression pattern in vascular smooth muscles and strict co-expression with smooth muscle ␣-actin (Fig. 2) .
Elevated Blood Pressure-Mice overexpressing the PMCA4b in vascular smooth muscles showed an ϳ10 mm Hg increase in left ventricular systolic pressure (Fig. 3) . The elevated blood pressure most likely reflects the higher muscular tone of the vascular smooth muscles in the PMCA-overexpressing mice.
Expression of nNOS and Interaction of nNOS with PMCA4 in Vascular Smooth
Muscle Cells-To test the hypothesis that the in vivo changes in blood pressure may be because of interaction of PMCA4b and NOS as described previously by us (16), we looked for co-expression and interaction of nNOS and endogenous PMCA4 in vascular smooth muscle cells. Endogenous PMCA4 staining was observed in sections of various organs. As an example, staining of wild type aorta with a mouse PMCA4-recognizing antibody is shown in Fig. 4 . nNOS expression in vascular smooth muscle cells was observed in all mouse tissue sections investigated. As an example, nNOS expression in control mouse aorta is shown in Fig. 5 , A-F. These results confirm previously published reports showing nNOS expression in vascular smooth muscle cells of hamsters (19) and extend it to mouse tissues. with the polyclonal anti-PMCA4 serum in wild type (wt) and transgenic (tg) animals. The right panel demonstrates coprecipitation of nNOS with PMCA4 but also co-precipitation with hPMCA4b (last lane) in aorta lysate of transgenic mice, using the specific antibody JA3. No precipitation with the human PMCA4b-specific antibodies (JA3) was observed in control animals, and no signal was obtained using an irrelevant (irrel.) antibody (antiestrogen receptor ␤).
Physical interaction of PMCA4 and nNOS was tested by co-immunoprecipitation. nNOS was co-precipitated by PMCA4-specific antibodies from wild type and transgenic aorta lysate (Fig. 5G) , demonstrating interaction of proteins in vascular smooth muscles. Interaction of endogenous nNOS with transgenic hPMCA4b was detected in co-precipitation assays using the human PMCA4b-specific antibody JA3 to precipitate the hPMCA4b-and nNOS-containing complex.
Typically, we observed an ϳ2-3-fold overexpression of PMCA4b on the protein level in transgenic animals. A representative example of expressed and precipitated total PMCA4 is given in Fig. 5G (left panel) , suggesting a physiologically relevant level of overexpression. Taken together, these results provide evidence for co-expression and interaction of transgenic hPMCA4b, the endogenous PMCA and nNOS in vascular smooth muscle cells.
Endothelium-dependent Relaxation-To evaluate the impact of PMCA on the regulation of vascular tone, endothelium-dependent and -independent relaxation was evaluated in preconstricted aortic rings. In PMCA4b transgenic animals, endothelium-dependent relaxation to acetylcholine did not differ from wild type littermates (76 Ϯ 8% versus 79 Ϯ 8% for maximum relaxation, n.s., Fig. 6A ). In nNOS knock-out mice, maximum endothelium-dependent relaxation was impaired compared with control mice, thus reflecting some impact of nNOS-derived NO on endothelium-dependent relaxation (Fig. 6B) , whereas acetylcholine concentration of half-maximal relaxation (pD 2 ) was similar in nNOS knock-out mice and nNOS controls (4.8 ϫ 10 Ϫ8 mol/liter versus 5.2 ϫ 10 Ϫ8 mol/liter acetylcholine, n.s., Fig. 6 ).
Endothelium-independent Relaxation-Endothelium-independent relaxation to the NO donor sodium nitroprusside was similar in PMCA transgenic mice and their wild type littermates (n.s., Fig. 7A ) and in nNOS knock-out mice as compared with their corresponding nNOS controls (n.s., Fig. 7B ), demonstrating that signaling pathways downstream the NO production remained unaltered in both PMCA transgenic and nNOS knock-out mice.
Concentration-dependent Contraction to Potassium Chloride (KCl)-De-endothelialized aortic rings of PMCA transgenic mice exhibited increased maximum contraction to KCl as compared with their wild type littermates (86 Ϯ 6% versus 68 Ϯ 7% of reference KCl contraction; p Ͻ 0.05; Fig. 8A ). In vitro preincubation of de-endothelialized vessel rings with the NOS inhibitor L-NAME (10 Ϫ5 mol/liter) resulted in a marked increase in contraction to KCl (p Ͻ 0.05 versus the corresponding group without L-NAME preincubation; Fig. 8A ), thus unmasking vasodilatory effects of underlying NO production. Maximum contraction to KCl after preincubation with L-NAME did not differ between PMCA transgenic animals and their wild type littermates (111 Ϯ 7% versus 105 Ϯ 7% of reference KCl contraction, respectively; n.s.; Fig. 8A ), which indicates that in PMCA transgenic mice basal NO production may be reduced.
FIG. 6. Endothelium-dependent relaxation of aortic segments.
A, endothelium-dependent relaxation to acetylcholine in aortic segments of PMCA4b transgenic mice and their wild type littermates given in % of preconstriction/norepinephrine (10 Ϫ7 mol/liter). Results are given as mean Ϯ S.E. (n ϭ 6 per group). For symbols without error bars the S.E. was less than symbol size. B, endothelium-dependent relaxation to acetylcholine in aortic segments of neuronal nitric oxide synthase (nNOS) knock-out mice and nNOS controls given in % of preconstriction/norepinephrine (10 Ϫ7 mol/liter. Results are given as mean Ϯ S.E. (n ϭ 5 per group). For symbols without error bars the S.E. was less than symbol size.
FIG. 7.
Endothelium-independent relaxation of aortic segments. A, endothelium-independent relaxation to sodium nitroprusside in aortic segments of PMCA4b transgenic mice and their wild type littermates given in % of preconstriction/norepinephrine (10 Ϫ7 mol/liter). Results are given as mean Ϯ S.E. (n ϭ 6 per group). For symbols without error bars the S.E. was less than symbol size. B, endotheliumindependent relaxation to sodium nitroprusside in aortic segments of neuronal nitric oxide synthase (nNOS) knock-out mice and nNOS controls given in % of preconstriction/norepinephrine (10 Ϫ7 mol/liter). Results are given as mean Ϯ S.E. (n ϭ 5 per group). For symbols without error bars the S.E. was less than symbol size.
In keeping with the results in PMCA transgenic mice, contractions of de-endothelialized aortic rings of nNOS knock-out mice to KCl were significantly elevated compared with their nNOS controls (151 Ϯ 5% versus 131 Ϯ 6% of reference KCl contraction; p Ͻ 0.05; Fig. 8B ), thus demonstrating the vasodilatory role of nNOS-derived NO.
DISCUSSION
The present results provide the first insight into the hitherto unknown function of the sarcolemmal calcium pump PMCA in the vascular system. In transgenic mice overexpressing isoform 4b (also named CI) of the pump in the vasculature, we found 1) an increase in blood pressure, 2) unaltered endothelium-dependent relaxation, and 3) increased vascular contraction in response to depolarization. These results were supported by pharmacological inhibition of NO synthesis as well as in nNOSdeficient mice. These alterations are likely because of reduced generation of nitric oxide and related to regulation of NO synthase I by the PMCA via physical interaction of the two enzymes. Hence, the PMCA is a novel candidate in the gamut of molecules regulating vascular tone.
At first glance, our results may seem surprising. Superficially, a pump ejecting calcium from the cytosol would be assumed to contribute to smooth muscle relaxation and hence a fall in blood pressure. The idea that anomalies in calcium regulation bear an intimate relationship to the regulation of blood pressure has been a major school of thought in the field of hypertension. Blaustein's hypothesis states that the sodium electrochemical gradient across the sarcolemmal membrane plays a critical role in cellular calcium regulation. Any change in the sodium gradient will then, presumably by an Na ϩ /Ca 2ϩ exchange mechanism, be reflected as a change in free intracellular Ca 2ϩ and, therefore, as a change in vessel wall tension (23) . The importance of the Na ϩ /Ca 2ϩ exchanger has been demonstrated recently (24 -26) , and a host of literature demonstrates that smooth muscle cytosolic calcium not only leads to contraction but also influences myosin light chain phosphorylation (reviewed in Ref. 27 ).
Why then, should overexpression of the sarcolemmal calcium pump PMCA in vascular smooth muscle cells lead to an increase in contractility and blood pressure? Over several years and using several independent experimental approaches, we have provided evidence for our hypothesis that the PMCA is involved in the regulation of signal transduction rather than direct regulation of contraction (12) .
In support of our hypothesis, we have shown that the pump is involved in skeletal muscle differentiation (28, 29) and that its overexpression in the myocardium of transgenic rats significantly alters response to hypertrophic stimuli, but not excitation/contraction coupling (12) . Recently, based on the finding of Strehler and co-workers that isoform 4b (CI) of the pump carries a C-terminal peptide sequence able to bind to PDZ protein domains (13), we have been able to show that this major isoform binds to the PDZ domain of nNOS and regulates it through its Ca 2ϩ /calmodulin dependence. Increasing the activity of the PMCA depletes Ca 2ϩ in the vicinity of nNOS and hence down-regulates its activity; this regulation has functional relevance in cellular cGMP physiology (16) . Previously published results (30) describing an nNOS-and cGMP-dependent response of fast-twitch skeletal muscle are in line with our observations.
The present study extends this concept to the vasculature. We show that nNOS and PMCA are colocalized in vascular smooth muscle sarcolemma. Additionally, physical interaction of the two proteins in lysates of aorta was shown here. In contrast to the wild type situation, NOS inhibition by L-NAME had no effect in endothelialized vessels overexpressing PMCA, in keeping with our previous in vitro finding that increasing PMCA down-regulates nNOS activity (16) . The specific functions of PDZ domain-containing nNOS␣ splice variants (31) and the specificity of interaction with PMCA variants and isoforms in different organs remain to be clarified. Our results (as shown in Fig. 5G ) suggest specific preference of interaction of nNOS␣ variants with certain PMCA variants. Post-translational modification, e.g. phosphorylation (6 -8) or C-terminal truncation of the PMCA4b (32), may account for different migration patterns and specific interactions with certain nNOS splice variants. C-terminal truncation of PMCA4b, as previously described to occur in brain tissues (32) , may also be responsible for the lack of signals in certain organs (e.g. small intestine) because the antibody was generated against the last 15 amino acid residues of hPMCA4b.
In summary, we here show that the sarcolemmal calcium pump is capable of regulating vascular tone and blood pressure in a whole animal model, and we propose a potential mechanism of action, i.e. regulation of vascular smooth muscle nNOS. Gros, Husain, and co-workers (33) observed an almost identical 10 mm Hg elevation of blood pressure in an inducible, smooth muscle-specific PMCA4b-overexpressing mouse model, attesting to the robust influence of the PMCA and virtually excluding any major effect of transgene insertion.
It will be revealing to identify other interaction partners of the pump and to characterize the vascular phenotype of PMCA knock-out models in the future. These results place the sarcolemmal calcium pump in the group of candidate genes for the polymorphic trait of blood pressure. Ϫ5 mol/liter, respectively. Results are given as mean Ϯ S.E. (n ϭ 6 per group). For symbols without error bars the S.E. was less than symbol size. *, p Ͻ 0.05 versus wild type littermates. **, p Ͻ 0.05 versus the corresponding group without L-NAME preincubation. B, concentration-dependent contraction to potassium chloride (KCl) in de-endothelialized aortic segments of neuronal nitric oxide synthase (nNOS) knock-out mice and nNOS controls. Results are given as mean Ϯ S.E. (n ϭ 5 per group). For symbols without error bars the S.E. was less than symbol size. *, p Ͻ 0.05 versus wild type littermates.
